FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to methods of administering a cell population enriched with tumour-reactive T cells, which can be used in medicine. Method includes: (a) obtaining a bulk population of T cells from a tumour sample; (b) specifically selecting CD8+ T cells that are (I) 4-1 BB+/PD-1+, (II) 4-1 BB+/LAG-3+ or (III) 4-1 BB+/TIM-3+ from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched with tumour-reactive T cells, that are also used to produce a pharmaceutical composition.
EFFECT: invention makes it possible to obtain a population of tumour-reactive cells, which provides high effectiveness of treating tumours.
33 cl, 8 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T-CELLS FROM A TUMOR | 2018 |
|
RU2808817C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| IMMUNOTHERAPY METHODS | 2017 |
|
RU2756276C2 |
| EXPANSION OF LYMPHOCYTE WITH A CYTOKINE COMPOSITION FOR ACTIVE CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2739770C2 |
| BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF | 2015 |
|
RU2743657C2 |
| METHOD OF OBTAINING A CULTURE OF LYMPHOCYTES ENRICHED IN TUMOR-SPECIFIC T-LYMPHOCYTE CLONES AND CELL CULTURES OBTAINED USING THE SPECIFIED METHOD | 2022 |
|
RU2808595C1 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | 2013 |
|
RU2650805C2 |
| METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS | 2014 |
|
RU2713333C2 |
| T CELLS RE-TARGETED WITH RESPECT TO CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR, AND METHODS FOR USE THEREOF | 2014 |
|
RU2711114C2 |
